Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. Like AML, blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a myeloid malignancy. It is a rare malignancy characterized by the aggressive proliferation of precursors of plasmacytoid dendritic cells that frequently involves the bone marrow, skin, central nervous system, and other organs and tissues. This discussion section focuses on the diagnosis and management of BPDCN as outlined in the NCCN Guidelines for AML.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Skin Neoplasms
- Oncology & Carcinogenesis
- Medical Oncology
- Leukemia, Myeloid, Acute
- Humans
- Hematologic Neoplasms
- Dendritic Cells
- Adult
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Skin Neoplasms
- Oncology & Carcinogenesis
- Medical Oncology
- Leukemia, Myeloid, Acute
- Humans
- Hematologic Neoplasms
- Dendritic Cells
- Adult
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis